INTRODUCTION
Skeletal muscle is a dynamic tissue that has the capacity to continuously regulate its size in response to a variety of external cues including mechanical load, neural activity, hormones/growth factors, stress and nutritional status. In addition, skeletal muscle serves as the most significant repository for protein in the body, a source that is tapped to provide a pool of amino acids for tissue repair and gluconeogenesis under conditions of starvation and other metabolic stresses. Muscle loss or "atrophy" occurs as the result of a number of disparate conditions including aging, immobilization, metabolic diseases, cancer, neurodegenerative diseases, and as a serious side effect of therapeutic corticosteroid hormone treatment (15, 27, 32) . The recently identified E3 ubiquitin ligase, MuRF1, is proposed to be a key regulator of the atrophy process given that (i) it is expressed predominantly in skeletal muscle (3) , (ii) it is upregulated under a variety of atrophy conditions (3, 12, 25) , and (iii) deletion of the gene in mice results in significant muscle sparing following denervation (3) . While the full physiological functions of MuRF1 are not yet known, it is often assumed that it functions in some manner to regulate protein degradation since it is expressed early in the atrophy process and its peak expression usually occurs during maximum muscle loss. For example, MuRF1 has been shown to play a direct role in myosin heavy chain ubiquitination and degradation during synthetic glucocorticoid treatment (5) . However, MuRF1 may have additional important functions in skeletal muscle, such as inhibition of protein synthesis during starvation conditions (22) , as well as regulating carbohydrate metabolism (16) . Despite considerable interest in MuRF1 as a regulator of skeletal muscle mass and metabolism, there is limited data on the transcriptional regulation of the MuRF1 gene.
Both natural and synthetic glucocorticoid hormones are potent inducers of skeletal muscle atrophy (14). Glucocorticoids exert their physiological actions primarily via a nuclear pathway to directly affect target gene transcription. Natural glucocorticoids such as cortisol and corticosterone, as well as synthetic glucocorticoids such as dexamethasone (DEX) and prednisolone, exert their biological effects predominantly via the glucocorticoid receptor (GR) (56) . The GR is a member of the nuclear receptor superfamily, and acts as a ligand dependent transcription factor. Skeletal muscle expresses significant Page 4 of 41 levels of GR, as do cultured myotubes. In the absence of ligand, the GR is found largely in the cytoplasm in a large complex that includes chaperones such as heat shock protein 90. Upon ligand binding, the GR becomes localized in the cell nucleus and binds to DNA sequences called glucocorticoid response elements (GREs). The consensus GRE sequence is AGAACANNNTGTTCT, where two GRs bind to each six nucleotide half-site of the palindome as a homodimeric complex (2). The three base-pair spacer sequence (NNN) can consist of any nucleotide combination, although that particular sequence length is critical. However, the perfect consensus sequence is rarely found in native glucocorticoid responsive promoters, with two or more nucleotide differences often found in either or both half-sites (45) . In addition, GR may positively or negatively influence transcription of target genes in a GRE-and homodimer-independent manner, via interaction with promoter bound STAT5, AP-1, or NF B transcription factors (reviewed in 50). Development of a mouse strain expressing a dimerization deficient GR (GR dim ) has allowed the identification of physiological processes and specific gene expression that are dependent on the classical GRE binding activity of the GR versus an indirect action through other transcription factors (38, 39) .
Although the synthetic glucocorticoid DEX induces MuRF1 mRNA accumulation in vivo as well as in cultured myotubes (3, 48) , it is currently unknown whether the gene is directly regulated by ligandbound GR in vivo. DEX induction could be mediated by the increased expression of other transcription factors and associated coactivators, that in turn bind to and activate the MuRF1 promoter. For example, the class O type forkhead transcription factors, including FOXO1, FOXO3a, and FOXO4, have been recently implicated as key regulators of gene expression during skeletal muscle atrophy (42, 48) .
FOXO1, FOXO3a and FOXO4 are all expressed in skeletal muscle (17) , and FOXO1 and FOXO3a mRNA in particular are up-regulated during fasting and DEX treatment (9, 25) . Constitutively active FOXO proteins can activate the endogenous MuRF1 gene (42, 48) ; however, there is no information on the direct effect of FOXO proteins on the MuRF1 promoter.
Recently, it has been demonstrated that up-regulation of MuRF1 expression following DEX treatment or starvation of C 2 C 12 cells can be suppressed by IGF-1 (41, 42, 48) . The mechanism by which IGF-1 is able to suppress MuRF1 transcription is believed to be at least in part via the PI3kinase/Akt pathway. Akt phosphorylates members of the FOXO class of forkhead transcription factors (40, 60) , and phosphorylated FOXOs are sequestered in the cytoplasm by 14-3-3 proteins, thereby inhibiting transcription of FOXO target genes. In addition, FOXO proteins lacking Akt phosphorylation sites prevent IGF-1 inhibition of DEX induction of MuRF1 (48) . Nevertheless, significant questions remain as to whether nuclear FOXO transcription factors alone are sufficient to activate transcription of the MuRF1 gene. In the present study, we provide a detailed analysis of the regulatory elements governing MuRF1 induction following glucocorticoid treatment, with particular attention to the role of the GR and specific FOXO transcription factors.
MATERIALS AND METHODS
Cell culture-HepG2 and C 2 C 12 cells were cultured in DMEM supplemented with 10% FBS, nonessential amino acids, and antibiotics and grown at 37°C in 5% CO 2 . C 2 C 12 cells were cultured in DMEM, supplemented with 10% FBS, non-essential amino acids, and antibiotics and grown at 37°C in 5% CO 2 .
C 2 C 12 myoblasts were differentiated to myotubes by switching confluent cells (usually 24-48 hours postsplit) to DMEM supplemented with 2% charcoal dextran treated FBS, non-essential amino acids, and antibiotics and grown for an additional 48-96 hours at 37°C in 5% CO 2 . All cell culture reagents except charcoal dextran treated FBS (Hyclone) were from Invitrogen.
Plasmids-The pSG5-GR construct was a kind gift of Dr. Stoney Simons, the pcDNA3-FoxO1 construct was provided by Dr. Masahiko Negishi, pCMV5-cMyc-FoxO3a was provided by Dr. Dominic Accili, and pcDNA3-FoxO4 was provided by Dr. Karen Arden. The pcDNA3.1-GRwt construct contains the fulllength mouse GR cDNA and the pcDNA3.1-GR dim construct was derived from pcDNA3.1-GRwt by overlap-PCR introducing the A458T point mutation and a novel BsrGI restriction site similar to the strategy use to create the same point mutation in the GR dim mouse targeting vector described previously (38). The mouse MuRF1 proximal promoter region was obtained by PCR from BAC clones RP23-40E12 (CHORI). BAC DNA was isolated from bacterial cultures using the BACMAX DNA Purification Kit AAC AAC TAT GTA AAC AAC TAT AAG TAA ACA ACT ATG TAA ACA ACT   ATA AGT AAA CAA CTA TGT AAA CAA GAT C-3' and 6X-DBE-R 5'-CTA GGA TCT TGT TTA CAT   AGT TGT TTA CTT ATA GTT GTT TAC ATA GTT GTT TAC TTA TAG TTG TTT ACA TAG TTG TTT ACT T-3'. The complementary oligo sequences were annealed by mixing and heating to 95°C and slowly cooling to 25°C over a 35 minute period using a thermocycler. The annealed oligos were then ligated into the SpeI site of the TK-Luc vector (kindly provided by Dr. Ronald Evans). The resulting recombinant plasmids were then restriction digested to confirm the presence of an insert and sequenced to determine the number and orientation of the concatemerized oligos. Site-directed mutagenesis of the FBE and GRE in the pGL3-and pSEAP-MuRF1-Pro500 constructs was performed essentially as described in the Site- myotubes were lysed and -galactosidase activities were determined and used to correct for variations in secreted alkaline phosphatase (SEAP) activities resulting from variations in transfection efficiencies.
For C 2 C 12 Northern blot experiments, cells were differentiated and treated as above, and total RNA was isolated using using RNeasy columns (Qiagen) according to the manufacturer's instructions.
Northern analysis was conducted using random-hexamer labeled MuRF1 and rpL8 cDNAs essentially as described previously (8) . muscle was isolated and analyzed by Northern hybridization using MuRF1, FOXO1, and FOXO3a, and rpl32 cDNA probes as described above. The beads were then pelleted by centrifugation at 3000 x g for 2 minutes. After removing the supernatant by careful aspiration, 100 µl of 10% Chelex-100 (BioRad) was added to the beads, followed by vortexing and incubation at 95 °C for 10 minutes to reverse the cross-linking. 2 µl of 20U/ml Proteinase K solution (Invitrogen) were added, followed by vortexing and incubated at 55 °C for 30 minutes, followed by heat inactivation at 95 °C for 10 minutes. After centrifugation at full speed in an Eppendorf microfuge for two minutes, the supernatant was transferred to a new tube and combined with a second extraction of the Chelex beads with 100 µl of water. Input (non-immunoprecipitated chromatin) was prepared by adding 100 µl of 10% Chelex directly to 100 µl of the diluted chromatin extract and processed as above. 
Chromatin immunoprecipitation (ChIP

RESULTS
The MuRF1 promoter contains a conserved near perfect palindromic glucocorticoid response element.
Since MuRF1 is known to be induced by synthetic glucocorticoids, as well as in several catabolic conditions associated with elevated endogenous glucocorticoids, we sought to identify the key glucocorticoid responsive elements in the gene. We began by isolating BAC clones encompassing the entire mouse MuRF1 transcription unit, and amplifying 5000 base pairs upstream of the transcription start site of the gene. Human, rat and mouse promoter sequences were aligned to detect conserved sequences Figure 4B ). Both the GRE and the adjacent FBE play an important role in the observed GR-FOXO synergy. DEX induction of the 500 base pair MuRF1 promoter is nearly abolished when the GRE is mutated and is completely abolished when the GRE is intact but the adjacent FOXO site is mutated ( Figures 4C and D) .
DEX induction of MuRF1 expression is inhibited in GR dim mice that express a dimerization deficient GR.
The functional significance of the near perfect GRE in the MuRF1 promoter was tested in vivo through the use of the GR dim mutant mouse strain that expresses a GR with a point mutation in the DNA binding domain that prevents binding of the GR to classical, palindromic GREs (38). This mutant GR still retains the ability to be tethered to target genes via protein-protein interactions such as the NF B or AP-1 transcription factor complexes. Both wild-type and GR dim mice were treated with water soluble DEX either by injection (6 and 24 hour time points) or in the drinking water (24 hour, 3 day, and 8 day time points). The experiment was terminated at 8 days of treatment due to the severe weight loss observed in the wild-type mice, which was not observed in the GR dim mice (p<0.001). As shown in Figure 5A , despite the inhibited overall body weight decline in GR dim versus wild-type mice in response to DEX, the degree of atrophy induced in the tibilialis anterior and gastrocnemius muscles was not statistically different in the two strains. By contrast, DEX induced splenocyte apoptosis was strongly inhibited in GR dim mice (p<0.001).
We next examined MuRF1 expression as well as FOXO1 and FOXO3a expression in GR dim versus GR +/+ mice ( Figure 5B ). MuRF1 expression is clearly up-regulated by six hours after DEX injection and continues to increase up to 3 days with continuous DEX treatment in wild-type mice.
MuRF1 induction is strongly inhibited in GR dim mice which is particularly apparent at the earliest time points. After eight days of DEX treatment, however, MuRF1 expression declines in wild-type mice until it is essentially equal to its induced expression in GR dim animals. In addition, FOXO1 and FOXO3a are also rapidly induced by DEX in wild-type mice, in agreement with a previous study (9) , and expression is reduced in GR dim mice at all time points tested. We then tested the ability of the homodimerization mutant GR expressed in GR dim mice to upregulate the proximal MuRF1 promoter, again using transient transfection assays ( Figure 5C ). The homodimerization mutant GR lost the ability to induce the MuRF1 promoter on its own, as expected, and showed a strongly reduced, but not completely abolished, ability to augment FOXO1 induction of the promoter. These transfection results may at least partially explain the residual DEX induced expression of MuRF1 in GR dim mice.
The glucocorticoid receptor and FOXO1 bind to the endogenous MuRF1 promoter in C 2 C 12
myotubes. Given the strong dependence on GR homodimerization in vivo for full MuRF1 gene induction, we next sought to determine the role of the GRE and FOXO1 sites in cultured skeletal myotubes. As we observed in HepG2 cells, the 500 base pair MuRF1 promoter is also DEX inducible in differentiated C 2 C 12 mouse skeletal myotubes ( Figure 6A ). DEX induction of the promoter is nearly abolished when the GRE is mutated and the adjacent FOXO site is intact, and completely abolished when the GRE is intact but the adjacent FOXO site is mutated ( Figure 6B) . Furthermore, addition of 20 ng/ml IGF-1 strongly inhibits DEX induction of the endogenous MuRF1 gene, as has been previously reported (41, 48) ( Figure   6C ), and IGF-1 likewise inhibits DEX induction of the MuRF1 promoter ( Figure 6D) . Therefore, the 500 base pair proximal promoter of MuRF1 contains the critical elements necessary to respond positively to glucocorticoids (via synergy with a forkhead site) and negatively to IGF-1 in a manner identical to the endogenous gene in differentiated myotubes.
In order to determine whether FOXO1 and GR can directly occupy the MuRF1 promoter in vivo, we The physiological relevance of having such a well-conserved, consensus GRE in the MuRF1 promoter is an interesting and important question.
Analysis of MuRF1 induction by DEX in GR dim mice revealed a critical role for GR homodimerization, which is most evident at the earliest time points examined in these experiments.
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Interestingly, despite the clear overall reduction in MuRF1 expression, as well as FOXO1 and FOXO3a, the degree of muscle atrophy in GR dim mice after eight days of DEX treatment was exactly the same in the mutant as in wild-type mice. Consequently, the residual level of MuRF1 expression in GR dim mice may well be enough to support full DEX induced atrophy. The rapid rise and gradual decline of MuRF1 expression we observed in DEX treated Balb/c mice is in agreement with experiments in rats dosed with the synthetic glucocorticoid prednisolone (1) . Concerning the mechanism of residual MuRF1 induction in GR dim mice, it is conspicuous that co-transfection of FOXO1 with the homodimerization mutant GR supports at least modest induction of the MuRF1 promoter in transient transfection assays, whereas the induction without FOXO1 is completely lost ( Figure 5 ). This is in line with the previous observation that the GR dim receptor by its own fails to bind to a palindromic GRE. Nevertheless, it is conceivable that FOXO1, when present together, still tethers the homodimerization mutant GR to the composite GRE-FBE motif, since protein-protein-interactions with other transcription factors are not compromised by the GR dim mutation. Regardless, it will be important to identify DEX responsive genes that are less affected enhanced by DEX treatment of C 2 C 12 cells along with the strong recruitment of GR (Figure 7 ), a situation also observed on the PEPCK and glucose-6 phosphatase genes (13, 51) , these proteins may be mutually bound and stabilized on the DEX activated MuRF1 promoter. Synergy may also be achieved via corecruitment of transcriptional coactivators such as histone acetyltransferases like CBP/p300 that have been shown to be independently recruited by the liganded GR or FOXO1 in other contexts (28, 34) .
Irrespective of the precise nature of the GR-FOXO1 synergy, our results reveal that each factor is required to create an optimal glucocorticoid inducible MuRF1 promoter.
There are several important implications of our findings on MuRF1 gene regulation. First, the activated glucocorticoid receptor may be an important player in the control of muscle atrophy, but the presence of nuclear FOXO1 is critical to achieve full induction of the MuRF1 promoter and, quite possibly, multiple glucocorticoid regulated genes in skeletal muscle. Furthermore, the glucocorticoid concentration needed to induce MuRF1 is significantly reduced in the presence of FOXO1. A logical prediction based on these results is that conditions with both elevated corticosteroids and active FOXO1
would lead to the greatest degree of muscle wasting and altered metabolism. In fact, diabetes mellitus presents such a condition (53) . In several models of diabetes, Akt is less active, potentially leading to decreased inhibition of FOXO activity and/or increased nuclear localization (55) . Elevated nuclear FOXO1 would be available to interact with the GR on the MuRF1 promoter to further induce the gene above the level induced by corticosteroids alone. Prolonged glucocorticoid exposure also leads to insulin resistance (54) , which might in turn lead to higher MuRF1 induction, accelerated muscle atrophy and metabolic changes as part of a vicious cycle. In contrast, the need for both nuclear FOXO1 and activated GR to fully activate MuRF1 may be protective and prevent unnecessary muscle breakdown. For example, following intense exhaustive exercise, circulating cortisol levels increase (6, 31) , yet elevated cortisol is generally not associated with an increase in the breakdown of contractile proteins, nor is loss of muscle mass a consequence of endurance training (33) . Thus, the need for additional factors to fully activate MuRF1 gene expression could protect the muscle from breakdown under certain physiological conditions.
In summary, our results demonstrate a potent synergy between the GR and FOXO1 in transcriptional control of an important gene linked to skeletal muscle atrophy and metabolic control. Comparison of a consensus GRE, and perfect palindrome GRE, and putative GREs from the mouse, rat and human MuRF1 promoters. Arrows indicate half-sites. 
